PRNewsWire
06 Jul 2026, 17:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The European Commission granted marketing authorization for TEPKINLY in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma. — Regulatory approval opens a new geographic market and expands the indicated use of the drug, creating a direct path to revenue growth for AbbVie.
+0.60The Phase 3 EPCORE FL-1 trial showed TEPKINLY + R2 reduced the risk of disease progression or death by 79% compared to R2 alone. — Strong clinical efficacy data increases the likelihood of rapid physician adoption and market share gains over standard of care.
+0.40The combination therapy achieved a complete response rate of 74%, significantly higher than the 43% seen with R2 alone. — High complete response rates reinforce the drug's competitive positioning and value proposition to payers and patients.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The European Commission granted marketing authorization for TEPKINLY in combination with lenalidomide and rituximab for the treatment of relapsed or refractory follicular lymphoma.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
20h ago
